Pharmacokinetics of cefodizime during continuous ambulatory peritoneal dialysis.
In a single-dose open cross-over trial we studied the pharmacokinetics of cefodizime 1 g in four uraemic patients treated by continuous ambulatory peritoneal dialysis (CAPD). Cefodizime was administered, successively with a wash out, (a) iv over 3 min and (b) by intraperitoneal (ip) administration together with the dialysate fluid (2 litres). Concentrations of cefodizime were measured by HPLC in blood and dialysate samples collected during an 8-h dwell period and in additional dialysate samples collected up to 48 h after drug administration. The mean (relative) total clearances following the iv and ip administration were 23 and 31 ml/min, respectively, and the terminal half-lives 5.5 and 6.7 h, respectively. Following iv administration, the peritoneal clearance was approximately 0.5 ml/min. After ip administration high concentrations of cefodizime were measured in the dialysate throughout the dwell period and systemic availability was good (80%) but variable.
Mendes
P
P
Clinical Research, Hoechst AG, Frankfurt, FRG.
Lameire
N
N
Rosenkranz
B
B
Malerczyk
V
V
Damm
D
D
D000328:Adult; D000368:Aged; D002439:Cefotaxime / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D002851:Chromatography, High Pressure Liquid; D006207:Half-Life; D006801:Humans; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory; D013056:Spectrophotometry, Ultraviolet; D014511:Uremia / Q000378:metabolism*
D002439:Cefotaxime; C033356:cefodizime